miR-19b在病毒性心肌炎中作用机制的研究
[Abstract]:Background Viral myocarditis (VMC) is the most common type of myocarditis, mainly caused by Coxsackievirus B (CVB). Statistics show that about 20% of the sudden infant death is caused by viral myocarditis or lethal ventricular arrhythmias caused by viral myocarditis and persists. The prognosis of active viral myocarditis is usually unsatisfactory, which seriously threatens the life and health of children. When persistent chronic inflammation occurs, it often leads to myocardial cell growth inhibition, hypertrophy, increased apoptosis rate, and further leads to myocardial fibrosis, dilated cardiomyopathy and heart failure. However, there is still no effective method to treat viral myocarditis at home and abroad. Therefore, looking for molecular markers for diagnosis of viral myocarditis is helpful to take effective measures to slow down or inhibit the progress of the disease, and can also be used as a molecular target to achieve the purpose of treatment. Previous studies have shown that the absence of MIR-19b expression can lead to ventricular septal defect in neonatal mice, suggesting that MIR-19b may be involved in early cardiac development. Although mi R-19b plays an important role in cardiac development, there are few studies on the relationship between MI R-19b and the occurrence and development of viral myocarditis. Objective To investigate the expression of MI R-19b in circulating blood of children with viral myocarditis. The aim of this study is to lay a foundation for the clinical diagnosis of viral myocarditis and the development of new targeted therapies. Methods (1) This study was collected from June 2014 to June 2015. Fifty children with viral myocarditis were hospitalized in the First Hospital of Jilin University.The expression of MI R-19b in peripheral blood samples was detected by fluorescence quantitative PCR.The expressions of C Tn I and CK-MB in serum were detected.The left ventricular ejection fraction (EF) and short axis shortening rate (FS) were measured. MiR-19b mimic and MI R-19b inhibitor were transfected into these cells. The expression of MI R-19b in the transfected cells was detected by fluorescence quantitative PCR. CVB3 was infected with these cells. Cell proliferation activity was detected by CCK-8 assay and apoptosis rate was detected by flow cytometry. The target gene of MI R-19b was predicted by software. TLR23'UTR (wild type) and TLR23'UTR-mut (mutant type) plasmids containing luciferase reporter gene were constructed and co-transfected with MI R-19b mimic to detect the expression of luciferase in neonatal rat cardiomyocytes. Then the above cells were infected with CVB3 and the expression of TLR2m RNA and protein was detected. (3) A rat model of viral myocarditis with overexpression of MIR-19b was established to detect the expression of MIR-19b in the myocardium of the above-mentioned model rats. Results (1) In severe VMC group, the expression of plasma MIR-19b was significantly higher in convalescence than in acute phase; in mild VMC group, the expression of plasma MIR-19b was significantly higher in convalescence than in acute phase. In the severe VMC group, the serum levels of C Tn I in convalescent stage were significantly lower than those in acute stage; in the severe VMC group, the serum levels of C Tn I in convalescent stage were significantly lower than those in acute stage. In mild VMC group, the serum CK-MB level was significantly lower in convalescent stage than in acute stage. EF test results showed that EF in severe VMC group was significantly lower than that in control group; EF in convalescent stage in severe VMC group was not significantly different from that in control group; EF in mild VMC group was not significantly different from that in acute stage; EF in convalescent stage in mild VMC group was significantly lower than that in control group. There was no significant difference between the two groups. There was a negative correlation between the level of plasma MIR-19b and the level of serum C Tn I in the acute stage of severe VMC. There was no significant correlation between the level of plasma MIR-19b and the level of serum C Tn I in the convalescent stage of severe VMC. There was a negative correlation between the level of plasma MIR-19b and the level of serum C Tn I in the acute stage of mild VMC. There was no significant correlation between the levels of plasma M I R-19b and serum C Tn I in the acute phase of severe VMC, but no significant correlation between the levels of plasma M I R-19b and serum C Tn I in the control group. There was no significant correlation between the levels of serum CK-MB and the levels of plasma MIR-19b in mild VMC. There was no significant correlation between the levels of serum CK-MB and the levels of plasma MIR-19b in convalescent VMC. There was no significant correlation between the level of plasma MIR-19b and EF in the convalescent stage of severe VMC, but no significant correlation between the level of plasma MIR-19b and EF in the acute stage of mild VMC, and no significant correlation between the level of plasma MIR-19b and EF in the convalescent stage of mild VMC. There was no significant correlation between the levels of plasma MIR-19b and serum EF. There was a positive correlation between the levels of plasma MIR-19b and FS in the acute stage of severe VMC. There was no significant correlation between the levels of plasma MIR-19b and FS in the convalescent stage of severe VMC. There was no significant correlation between the expression of MIR-19b and FS in the convalescent stage of mild VMC. There was no significant correlation between the expression of MIR-19b and FS in the control group. Compared with the control group, the survival rate of MIR-19b mimic group was significantly higher at 48, 72 and 96 hours, while that of MIR-19b inhibitor group was significantly lower at corresponding time points. TLR2 was the target gene of MI R-19b. The expression level of luciferase in neonatal rat cardiomyocytes co-transfected with wild-type TLR2 3'UTR vector carrying luciferase reporter gene and MI R-19b mimic was significantly decreased, but the expression level of luciferase in neonatal rat cardiomyocytes co-transfected with mutant TLR2 3'UTR vector and mir-19b mic was not found. The results of TLR-m RNA detection showed that the expression of TLR-m RNA in the cells of MIR-19b mimic group was significantly lower than that of the control group, while the expression of TLR-m RNA in the cells of MIR-19b inhibitor group was significantly higher than that of the control group. (3) The expression of MIR-19b in the myocardium of transgenic rats was significantly higher than that of the control group. After infection with CVB3, a large number of myocardial cells in normal SD rats necrosis and disintegration, nucleus and cell contour disappeared, and the expression of TLR protein in the myocardial interspace was observed. A large number of inflammatory cells were infiltrated, and the myocardial fibers were arranged disorderly in the infiltration site, and the myocardial tissue was destroyed. The number of myocardial cells disintegrated significantly after the infection of CVB3 in transgenic myocarditis rats, the nucleus and cell contour were clearer, and a small amount of inflammatory cells infiltrated into the myocardial space. The expression of TLR2 protein in myocardium of transgenic rats infected with CVB3 was significantly lower than that of normal SD rats. Conclusion (1) The expression of MIR-19b was decreased in viral myocarditis; (2) MIR-19b was associated with the severity and course of viral myocarditis; (3) MIR-19b was promoted by targeting inhibition of TLR2 expression. (4) MIR-19b has protective effect on myocardial cell injury caused by CVB3 infection, and its mechanism is related to the inhibition of TLR2 protein expression by MIR-19b, which can alleviate myocardial inflammation and inhibit cardiomyocyte apoptosis.
【学位授予单位】:吉林大学
【学位级别】:博士
【学位授予年份】:2017
【分类号】:R542.21
【相似文献】
相关期刊论文 前10条
1 莫祥兰,刘时才;病毒性心肌炎(附一例报告)[J];广西医学;2000年05期
2 马正义,郭彩云;中西医结合治疗病毒性心肌炎36例[J];河北中医;2000年02期
3 韦洪林,线丽波,于景峰;中西医结合治疗病毒性心肌炎疗效观察[J];黑龙江医学;2000年03期
4 谷俊,韩冬;病毒性心肌炎合并Ⅱ°~Ⅲ°房室传导阻滞15例临床分析[J];锦州医学院学报;2000年03期
5 陈淑华,曹文君;中西医结合治疗病毒性心肌炎62例[J];黑龙江医药科学;2000年02期
6 白秋彩,董良璞;病毒性心肌炎50例临床分析[J];中原医刊;2000年09期
7 ;警惕病毒性心肌炎[J];农村实用技术与信息;2000年12期
8 吴贵秋,米丽娟,关东英;应用果糖二磷酸钠注射液治疗病毒性心肌炎的效果观察[J];齐齐哈尔医学院学报;2000年04期
9 ;病毒性心肌炎诊断有了客观标准[J];山东中医药大学学报;2000年04期
10 崔秋颖,毕风丽;中西医结合治疗病毒性心肌炎48例[J];心血管康复医学杂志;2000年01期
相关会议论文 前10条
1 关键;王国干;孙筱璐;;强的松对病毒性心肌炎的保护作用[A];第三届重症医学大会论文汇编[C];2009年
2 陈其;张园海;仇慧仙;翁海美;夏天和;任跃;花旺;姜剑斌;荣星;吴蓉洲;;胱硫醚-γ-裂解酶/硫化氢通路在小鼠病毒性心肌炎中的表达[A];中华医学会第十五次全国儿科学术大会论文汇编(上册)[C];2010年
3 王连伟;张勇刚;高立功;李海明;龚全友;;654-2在病毒性心肌炎Ⅲ°房室传导阻滞中的应用[A];中华医学会急诊医学学会第六次全国急诊医学学术会议论文汇编[C];1996年
4 张广文;白雪;杨思进;;中药抗病毒性心肌炎的实验研究现状[A];第九次全国中医心病学术研讨会论文精选[C];2007年
5 徐海鹰;凌峰;于忠;许轶洲;杨俊;;病毒性心肌炎患者细胞免疫功能检测的临床价值[A];2012年浙江省心电生理与起搏学术年会论文集[C];2012年
6 胡以明;;中西医结合治疗气阴两虚型病毒性心肌炎临床体会[A];中国中医药学会内科学会第三届学术年会论文集[C];1997年
7 李宏图;;1+X治疗病毒性心肌炎的体会[A];中医药学术发展大会论文集[C];2005年
8 韩丽华;曾垂义;;144例病毒性心肌炎急性期病例分析[A];中华中医药学会内科分会学术年会资料汇编[C];2007年
9 张军平;周亚男;;成人病毒性心肌炎患者40例临床观察分析[A];中华中医药学会心病分会第十一届学术年会论文精选[C];2009年
10 吕仕超;张军平;;病毒性心肌炎诊断的困惑与对策[A];中华中医药学会心病分会全国第十二次学术年会暨中华中医药学会心病分会换届选举工作会议论文精选[C];2010年
相关重要报纸文章 前10条
1 李尤佳;病毒性心肌炎病后加强护理[N];健康时报;2007年
2 王小衡;病毒性心肌炎好发青年女子[N];大众卫生报;2007年
3 乔国维;病毒性心肌炎运动疗[N];医药养生保健报;2007年
4 ;患病毒性心肌炎宜多静养[N];医药导报;2008年
5 上海承志堂中医馆 朱邦贤 教授;“病毒性心肌炎”中医可防可治[N];上海中医药报;2009年
6 李尤佳;病毒性心肌炎不可小看[N];中国中医药报;2004年
7 伍新华;大黄有望成为病毒性心肌炎克星[N];大众卫生报;2005年
8 秦 秋;中医药治疗病毒性心肌炎取得成果[N];中国中医药报;2004年
9 何世桢;病毒性心肌炎患者宜静养[N];中国中医药报;2007年
10 ;莫劳累 不感冒 可防病毒性心肌炎[N];大众卫生报;2003年
相关博士学位论文 前10条
1 张圳;miR-19b在病毒性心肌炎中作用机制的研究[D];吉林大学;2017年
2 郑杨;病毒性心肌炎心肺相关性的研究[D];黑龙江中医药大学;2002年
3 沈茜;病毒性心肌炎病原分子杂交检测和免疫损伤机理的实验研究[D];第四军医大学;1991年
4 印芳颖;骨桥蛋白及其反义基因在病毒性心肌炎中表达及作用的研究[D];吉林大学;2007年
5 王菲菲;基于病毒性心肌炎文献分析的中医证候计量诊断及用药规律研究[D];南京中医药大学;2009年
6 关键;药物对病毒性心肌炎小鼠模型的影响[D];北京协和医学院;2009年
7 陈相健;病毒性心肌炎向扩张型心肌病转化的分子细胞机制及药物干预研究[D];南京医科大学;2001年
8 孙智勇;SB203580对病毒性心肌炎鼠的影响的实验研究[D];吉林大学;2009年
9 张建军;病毒性心肌炎心肌ICAM-1表达与细胞凋亡关系及药物干预作用的实验研究[D];山东大学;2006年
10 于侠;重组白介素-12对小鼠病毒性心肌炎治疗机制的研究[D];吉林大学;2007年
相关硕士学位论文 前10条
1 徐静;K-CoxB-JN复方新制剂对小鼠CVB_3性心肌炎的治疗作用[D];河北联合大学;2014年
2 董宁;ADAR1在病毒性心肌炎发病过程中作用及其机制研究[D];苏州大学;2015年
3 张鹏飞;益心解毒冲剂治疗病毒性心肌炎的临床研究[D];华北理工大学;2015年
4 张芸娟;黄芪注射液对病毒性心肌炎的治疗作用及对半胱天冬氨酸蛋白酶-3活性影响的研究[D];兰州大学;2015年
5 王超;IL-33在CVB3诱导的病毒性心肌炎中的作用及其机制[D];苏州大学;2015年
6 周晓敏;黄芪总黄酮对病毒性心肌炎鼠心肌细胞钙转运及内质网应激作用实验研究[D];内蒙古民族大学;2015年
7 卢娟;肠道病毒71型病毒性心肌炎小鼠模型的建立及3-氮唑核苷的干预[D];安徽医科大学;2016年
8 徐艳艳;病毒性心肌炎小鼠体内NT-proBNP的水平变化及意义[D];安徽医科大学;2016年
9 吴学洁;Sema7A在CVB3诱导的病毒性心肌炎中的作用及其机制[D];苏州大学;2016年
10 刘洪坤;基于临床证据的中药复方治疗病毒性心肌炎组方用药规律研究[D];山东中医药大学;2016年
,本文编号:2223755
本文链接:https://www.wllwen.com/shoufeilunwen/yxlbs/2223755.html